Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Humacyte (HUMA) Climbs +26% on Q3 Earnings Beat and Regulatory Momentum

Humacyte (HUMA) Climbs +26% on Q3 Earnings Beat and Regulatory Momentum

Key Takeaways

  • HUMA shares climbed roughly 26% over the past 30 days, from about $0.43 in mid-October to near $0.54, driven by a third-quarter earnings beat and upbeat guidance.
  • Symvess (acellular tissue engineered vessel) sales more than doubled sequentially to $1.0 million in Q3 2026, and October sales alone reached approximately $0.8 million.
  • Humacyte reiterated plans to file a supplemental Biologics License Application (sBLA) for the ATEV in dialysis access in November 2026, a key near-term regulatory catalyst.
  • Over the broader quarter, the stock has been volatile and essentially flat to modestly lower, reflecting a steep October sell-off toward $0.35 before the November rebound.
  • Analyst responses to the results were mixed, with Piper Sandler and Barclays maintaining Hold ratings while H.C. Wainwright reiterated a Buy.
  • For more detail on this ticker's Price Targets, Earnings, and Forecast, explore the dedicated analysis pages.
  • To see how AI-driven trading systems are positioning across thousands of tickers, explore Trending AI Robots.

Humacyte (HUMA) Company Overview and Market Position

Humacyte, Inc. is a Durham, North Carolina-based commercial-stage biotechnology company developing universally implantable, bioengineered human tissues at commercial scale. Its lead product, Symvess (the acellular tissue engineered vessel, or ATEV), received FDA approval in December 2024 for use as a vascular conduit in extremity vascular trauma repair. Beyond its approved indication, the company is advancing the ATEV in late-stage trials for arteriovenous access in hemodialysis and peripheral artery disease, and it has initiated a first-in-human Phase 2a study of its coronary tissue engineered vessel (CTEV) for coronary artery bypass grafting.

The company holds Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for several programs, and its platform underpins a pipeline that also includes preclinical work in type 1 diabetes and pediatric heart surgery. Investors follow HUMA for its first-in-class regenerative medicine platform, its early commercial ramp, and the regulatory milestones tied to the ATEV's expansion into the dialysis-access market. When assessing comparable names in the sector, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Humacyte (HUMA) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, HUMA has advanced approximately 26%, moving from a closing price of about $0.43 in mid-October to roughly $0.54 by mid-November. The move was concentrated around the company's third-quarter earnings release on November 10, when the stock rose roughly 24% intraday on heavy volume. Shares subsequently pulled back from a post-earnings peak near $0.59 as some investors locked in gains.

The longer quarterly picture tells a more volatile story. Over the roughly three-month period, the stock has been essentially flat to modestly lower in the low single digits. That headline masks a sharp drawdown: HUMA fell from around $0.56 to $0.58 in mid-August to an intraday low near $0.34 in mid-October, before the strong November recovery. The result is a pronounced V-shaped pattern in which the recent 30-day advance has yet to fully reclaim the stock's mid-summer levels.

What Drove HUMA Stock Price in the Last 30 Days

The primary catalyst was the third-quarter 2026 earnings report released on November 10. Humacyte reported Symvess sales of $1.0 million, a 151% sequential increase from $0.4 million in the second quarter and a 43% increase year over year. Total revenue of about $1.03 million exceeded consensus estimates by roughly 34%, while the company's net loss of $0.06 per share beat the roughly $0.10 loss analysts had expected. Hospital adoption expanded 44% sequentially, from 34 to 49 ordering sites, and management guided for fourth-quarter sales to at least double the third-quarter total.

Investors also responded to forward-looking milestones. Management confirmed that the sBLA for the ATEV in dialysis access remains on track for a November 2026 filing, supported by three Phase 3 studies, including the V007 trial published in The Lancet Digital Health and V012 data presented at ASN Kidney Week. The company additionally announced the initiation of its first-in-human Phase 2a CTEV study in coronary artery bypass grafting. On the analyst side, Piper Sandler maintained a Hold rating with a $1.00 price target, Barclays maintained a Hold, and H.C. Wainwright reiterated a Buy.

What Drove HUMA Stock Performance Over the Last Quarter

The quarter was defined by the company's commercial relaunch and a sharp repricing of its shares. Under Jim Mercadante, who joined as Chief Commercial Officer in May 2026, Humacyte rebuilt its commercial team, refined introductory pricing and education programs, and accelerated hospital onboarding. Sequential revenue growth and the expansion to 49 ordering hospitals reflected the early payoff of that strategy. Cost discipline also improved, with research and development spending declining sequentially and operating cash burn falling 37% year over year to $15.0 million in the third quarter, while cash and equivalents stood at $64.9 million.

At the same time, the stock's October sell-off reflected concerns common to pre-profitability biotech companies, including negative gross margins tied to unused production capacity, a still-modest revenue base, and the potential for future dilution. The November earnings beat and explicit fourth-quarter guidance helped reset sentiment, but the shares remain below their levels from earlier in the summer. I also checked this using Tickeron’s AI Pattern Search Engine to see how the stock compares to others in the industry.

HUMA Stock Forecast Drivers: What Investors Should Watch Next

Near-term attention centers on the planned sBLA submission for the ATEV in dialysis access and the FDA's subsequent acceptance and review-timeline decision. Investors will also watch the fourth-quarter Symvess sales trajectory against management's guidance to at least double Q3 revenue, as well as the pace of new hospital adoption and any disclosure on average selling prices and gross-margin improvement. The cash position and any future financing activity remain important given the company's ongoing operating losses. Clinical updates, including enrollment in the Phase 2a CTEV study and data presentations such as those scheduled for the VEITHsymposium, could also influence sentiment. As with any development-stage biotech, regulatory outcomes, reimbursement decisions, and broader market conditions will remain key variables.

Exploring AI-Driven Trading Strategies

I've found Tickeron's AI Trading Bots helpful for reviewing automated approaches across a wide range of tickers. The platform offers hundreds of AI robots that trade thousands of securities, with only the top-performing and most relevant systems highlighted for comparison. Users can evaluate different strategies, holding timeframes, and performance metrics to complement their own analysis. Those interested can explore the available bots and their recent results directly on the platform.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HUMA

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


HUMA's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for HUMA turned positive on October 21, 2026. Looking at past instances where HUMA's MACD turned positive, the stock continued to rise in 36 of 40 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on HUMA as a result. In 71 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.

HUMA moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for HUMA crossed bullishly above the 50-day moving average on November 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.

Following a +0.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where HUMA advanced for three days, in 194 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

The Aroon Indicator entered an Uptrend today. In 148 of 170 cases where HUMA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.

Bearish Trend Analysis

The 10-day RSI Indicator for HUMA moved out of overbought territory on November 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 21 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 53 cases where HUMA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

HUMA broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. HUMA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.983) is normal, around the industry mean (3.592). P/E Ratio (-0.862) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (52.083) is also within normal values, averaging (442.120).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
2525 East North Carolina Highway 54
Phone
+1 919 313-9633
Employees
184
Web
https://www.humacyte.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.
Humacyte (HUMA) Climbs +26% on Q3 Earnings Beat and Regulatory Momentum